• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » A New Contraindication for Ambien and the Z-Hypnotics

A New Contraindication for Ambien and the Z-Hypnotics

August 30, 2019
Chris Aiken, MD Talia Puzantian, PharmD, BCPP
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD Talia Puzantian, PharmD, BCPP Dr. Aiken and Dr. Puzantian have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
“Complex sleep behavior” is a euphemism for various problems that can happen after ingesting a sleeping pill. They range from cooking and emailing to driving a car or even sexual assault, all done in an amnestic state that is not recalled upon awakening. In 2007 the FDA placed warnings about these behaviors on all medications approved for insomnia, and this year they moved that warning up to a black-box level for the z-hypnotics: zolpidem (Ambien), zaleplon (Sonata), and eszopiclone (Lunesta). The new warning also applies to zolpidem’s various forms: CR, sublingual (Intermezzo, Edluar), and oral spray (Zolpimist).

The agency took this step to recognize the gravity of these parasomnias, which are too often the butt of jokes. They reviewed 26 years of adverse event reports and found 66 cases of complex sleep behaviors that resulted in either serious injuries (46 cases) or death (20 cases). Some of the cases involved accidental overdoses, falls, burns, near drowning, exposure to extreme cold temperatures leading to loss of limb, carbon monoxide poisoning, drowning, hypothermia, motor vehicle accidents with the patient driving, and self-injuries such as gunshot wounds and apparent suicide attempts.

Although severe events are very rare, complex sleep behaviors are fairly common and occur in 3%-15% of people on z-hypnotics. Zolpidem is the most notorious only because it is the most frequently prescribed—its risk is actually no different than the others in its class. With all z-hypnotics, the risk goes up as the dose goes higher (Chen LF et al, Neuropsychiatr Dis Treat 2013;9:1159-1162).

The most important part of this warning is the word “contraindication.” The FDA now recommends discontinuing z-hypnotics in anyone who has had a complex sleep behavior after taking them, however mild. Patients may protest that there’s nothing dangerous about microwaving popcorn at 2 a.m., but there’s always a risk that the problem might lead to a fractured skull or burnt arm.

Part of the reason for the absolute tone in this contraindication is that the benefits of z-hypnotics are so meager that it’s hard to justify their use in the face of these risks. On average, they cause people to fall asleep 22 minutes faster than a placebo by polysomnographic measures, and only 7 minutes faster by subjective report, according to a meta-analysis of the FDA-registration trials (Huedo-Medina TB et al, BMJ 2012;17;345:e8343). They do nothing to improve quality of sleep or long-term health outcomes. Patients seem to find these drugs more helpful than the research suggests, in part because there is a large placebo effect. People fall asleep 20-30 minutes faster with a placebo. The amnestic qualities may also explain why these drugs are so well liked: patients forget how poorly they slept.

Preventing Complex Sleep Behaviors



  1. Lower zolpidem in women
    Women eliminate zolpidem slower than men, resulting in higher rates of complex sleep behaviors and more impairment of morning driving. The FDA changed the starting dose of zolpidem in women from 10mg to 5mg in 2013 (or 6.25mg for Ambien CR). Among the z-hypnotics, zolpidem has the highest risk of morning impairment, so the FDA recommends that we aim for lower doses in men as well and that patients avoid driving the next day after taking Ambien CR.



  1. Watch for drug interactions
    Zolpidem and eszopiclone are metabolized through CYP3A4, so inhibition of this enzyme can result in higher levels of the hypnotic (strong inhibitors: nefazodone, -azole antifungals, antiretrovirals, erythromycin, and clarithromycin; weaker inhibitors include: verapamil, pimozide, cimetidine, and grapefruit juice). Zaleplon is not significantly metabolized through the p450 system and is less prone to pharmacokinetic interactions.



  1. Avoid other GABAA agonists
    Complex sleep behaviors are more likely to occur when z-hypnotics are taken with other GABAA agonists, which include alcohol, benzodiazepines, barbiturates, and some herbs that are used for sleep and anxiety like valerian, kava, and skullcap. Gabapentin does not seem to share in this pharmacodynamic interaction, but valproate, which has GABAA activity, can (Dolder CR & Nelson MH, CNS Drugs 2008;22(12):1021-1036).



  1. Don’t eat before bed
    Food delays the effects of zolpidem and eszopiclone by 1 hour and zaleplon by 2 hours. Delayed onset of sleep medicines is a risk factor for complex sleep behaviors and morning impairment. Patients should be advised not to eat within 30 minutes of taking these hypnotics.



  1. Switch to a different class
    The FDA recommends avoiding z-hypnotics if any complex sleep behaviors occur on them. Although all sleep medications have a blanket warning about these behaviors, it is mainly the GABAA agonists cause it: z-hypnotics and benzodiazepines. Suvorexant (Belsomra) has a slight risk (0.6%), while ramelteon, doxepin, hydroxyzine, trazodone, and melatonin appear free of the problem.



  1. Behavioral approaches
    Behavior therapy is recommended first-line for insomnia, before hypnotics (self-guided apps include CBT-i Coach and Restore CCBT; see TCPR Feb 2019).


General Psychiatry
KEYWORDS fda-warnings hypnotics insomnia news_of_note practice_tools_and_tips psychopharmacology psychopharmacology_tips sleep
Chris Aiken, MD Talia Puzantian, PharmD, BCPP

More from this author
www.thecarlatreport.com
Issue Date: August 30, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - How to Talk about Medication, TCPR, September 2019
Is There a Case for Cannabis in the Treatment of Pain?
Is Paxil the Best SSRI for Anxiety?
A New Contraindication for Ambien and the Z-Hypnotics
A New Way to Talk to Patients about Medication
Mirtazapine Augmentation: Running Low on Rocket Fuel
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.